Micro-Dystrophin Delivery: Assessing the Technological Hurdles and...

σε πρόσθεσε στο Health

2025-11-18 11:07:01 -

Micro-Dystrophin Delivery: Assessing the Technological Hurdles and Commercial Potential of AAV-Based Treatments in the Duchenne Muscular Dystrophy Market.

The micro-dystrophin gene therapy segment, which relies on Adeno-Associated Virus (AAV) vectors, represents the peak of technological achievement and commercial value in the Duchenne Muscular Dystrophy (DMD) market. This modality promises to deliver a one-time treatment that addresses the core genetic defect by ensuring muscle cells can produce a functional, albeit shortened, dystrophin...

0 Σχόλια 0 Μοιράστηκε 305 Views 0 Προεπισκόπηση